The Society for Immunotherapy of Cancer (SITC) will host the Summit on Intralesional Immunotherapy: Moving Beyond Oncolytic Viruses on Thursday, Sept. 19, from 10 a.m.–2 p.m. EDT. The virtual summit is a free, public event that features invited speakers, expert panel discussions, and attendee question and answer periods. The multi-stakeholder virtual summit will feature over 25 panelistsrepresenting academic research and industry around the world.
The SITC Summit on Intralesional Immunotherapy will highlight the latest translational and clinical research on intralesional immunotherapies and their impacts on the immune system, anti-tumor immunity, and the tumor microenvironment. Topics to be addressed at the summit include the current definitions of local immunotherapy, enhancing the effects of in situ vaccination, combining intralesional immunotherapies with other therapies, intralesional immunotherapy in the neoadjuvant setting, and high priority research areas for the field of intralesional immunotherapy.
This program will provide an up-to-date overview of current and emerging intralesional immunotherapies and their potential clinical impact. Didactic presentations and panel discussions will identify clinical and translational strategies, challenges, and opportunities in the field, highlighting intralesional immunotherapy as an important tool in the cancer immunotherapy toolbox.